Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 6, 2003, Pages 477-481

  Pearlman, Michael ^a   Jendiroba, David ^a   Pagliaro, Lance ^a   Keyhani, Afsaneh ^a   Liu, Baoshun ^a   Freireich, Emil J ^a   Travis, Elizabeth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dexrazoxane; Gastrointestinal toxicity; Mucositis

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; IDARUBICIN; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CRYPT CELL; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; INCIDENCE; JEJUNUM; MALE; MOUSE; MOUSE STRAIN; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOXORUBICIN; IDARUBICIN; INJECTIONS, INTRAPERITONEAL; JEJUNAL DISEASES; JEJUNUM; MALE; MICE; MICE, INBRED C3H; PROTECTIVE AGENTS; RAZOXANE;

EID: 0344513361     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0655-3     Document Type: Article

References (16)

1. Allan WP, Thampatty P, Fattman CF, Hasinoff BB, Yalowich JC (1997) Inhibitory effects of ICRF-187 and aclarubicin on etoposide (VP-16) induced topoisomerase II-DNA complexes in human leukemia K562 and HL-60 cells: Relationship to topoisomerase II level and function (Meeting abstract no. 38). Proceedings Annual Meeting of the American Association of Cancer Research
2. Basser RL, Sobol MM, Duggan G, Cebon J, Rosenthal MA, Mihaly G, Green MD (1994) Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 12:1659-1666
3. Hasinoff BB (1998) Chemistry of dexrazoxane and analogues. Semin Oncol 25 [4 Suppl 10]:3-9
4. Herman EH, el-Hage A, Ferrans VJ (1988) Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92:42-53
5. Lopez M, Vici P, Di Lauro K. Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D, Maini CL (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16:86-92
6. Pearlman M, Jendiroba D, Pagliaro L, Keyhani A, Liu B, Freireich EJ (2003) Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk Res 27:617-626
7. Pharmacia (1996) Investigators' brochure for Zinecard (dexrazoxane). Pharmacia & Upjohn Company, Kalamazoo, MI
8. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, et al (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. New Engl J Med 319:745-752
9. Speyer JL, Green MD, Sanger J, Zeleniuch-Jacquotte A, Kramer E, Rey M, Wernz JC, Blum RH, Hochester H, Meyers M, et al (1990) A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 17:161-163
10. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer [published erratum appears in J Clin Oncol 1992;10(5):867]. J Clin Oncol 10:117-127
11. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy [see comments]. J Clin Oncol 15:1333-1340
12. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332
13. Trotti A (1997) Toxicity antagonists in cancer therapy. Curr Opin Oncol 9:569-578
14. Von Hoff DD (1998) Phase I trials of dexrazoxane and other potential applications for the agent. Semin Oncol 25 [4 Suppl 10]:31-36
15. Wang G, Finch MD, Trevan D, Hellmann K (1981) Reduction of daunomycin toxicity by razoxane. Br J Cancer 43:871-877
16. Withers HR, Elkind MM (1970) Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med 17:261-267